Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totaling 27,890 shares, a drop of 50.2% from the June 15th total of 56,055 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 314,176 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. raised its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 976,448 shares of the company’s stock after buying an additional 332,055 shares during the period. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Biofrontera Stock Up 1.9%

Shares of NASDAQ:BFRI traded up $0.02 on Wednesday, hitting $1.08. 136,480 shares of the company traded hands, compared to its average volume of 352,915. The stock has a 50 day simple moving average of $0.97 and a 200-day simple moving average of $0.92. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. The company has a market cap of $13.82 million, a PE ratio of -1.11 and a beta of 0.81. Biofrontera has a 52 week low of $0.55 and a 52 week high of $1.21.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.29). The firm had revenue of $10.08 million for the quarter, compared to analysts’ expectations of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. As a group, research analysts expect that Biofrontera will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BFRI. Weiss Ratings downgraded Biofrontera from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Zacks Research lowered Biofrontera from a “hold” rating to a “strong sell” rating in a research report on Friday, July 3rd. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.